Welcome to our latest issue of EMJ Hematology, which brings you quality content on the latest developments in the field and a review of the European Hematology Association (EHA) 2022 Hybrid Congress, with key highlights from the event. Featured articles include a review of the social impact and quality of life for patients with β-thalassaemia, and an article on how helical tomotherapy may be used as a valid and effective treatment for compressive atelectasis due to extramedullary haematopoiesis.
EMJ Hematology 10.1 2022
Latest articlesAll articles
Extension Treatment: Preventing Recurrence of Venous Thromboembolism
VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), affects approximately 1–2 in every 1,000 people annually.2 It is a major cause of death and disability in England, with thousands of deaths directly attributed to the condition each year.
Infographic: Differences in Mechanism of Action and Selectivity of Covalent and Non-Covalent BTK Inhibitors
Infographic: Differences in Mechanism of Action and Selectivity of Covalent and Non-Covalent BTK Inhibitors. Provided by Clinical Care Options, LLC. Supported by an educational grant from Lilly.
Infographic: Perceptions of Treatments in AML – A Survey of 375 European Haematologists
Acute myeloid leukaemia (AML) is a rapidly progressing haematological cancer with a poor prognosis. This infographic summarises the key results from an online survey conducted in 2022 on the perceptions of AML treatments among clinicians in Europe. Haematologists and oncologists from five European countries were asked their opinions on topics such as first-line treatments, the intensity of treatment regimens, and therapies for curative intent for patients with AML.